Brief Summary
The aim of this study is to evaluate the safety and feasibility of Endobronchial thermal liquid ablation (ETLA-LC) for the Treatment of Pulmonary Cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs Lesions.
Intervention/Treatment
- Device: Endobronchial Thermal Liquid Ablation – Lung Cancer (ETLA-LC).
Inclusion Criteria
General Inclusion Criteria:
- Age greater than or equal to 18 years old.
- Non-small cell lung cancer tumor(s) suitable for lobectomya surgical procedure where a lobe of an organ (e.g. the lung) is removed.
- Suitable candidate for lobectomy as per standard of care.
- Pathologically confirmed malignancy obtained via bronchoscopic biopsyremoval of a section of tissue to analyse for cancer cells with adequate yield to perform definitive diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results.
- Cognitively able to provide written informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment..
Radiographic Inclusion Criteria
- Longest axis of tumor less than 3cm per HRCT analysis by QCT Core lab.
- Tumor is identified in the periphery of lung (outer 2/3rd) by radiologic reviewer in addition to site radiologist.
- Tumor resides in eligible segment(s) per HRCT analysis by QCT Core lab, with target treatment location not adjacent to lobar fissure planned for resectionsurgical removal of tissue or part/all of an organ, and assessed by surgeon.
- Tumor resides within two or fewer eligible segments per HRCT analysis by QCT Core lab with treatment at the segmental or subsegmental level.